The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19

COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Mohammad Ali, Sherafat, Alireza, Pourdast, Alieh, Nazemi, Pershang, Mohraz, Minoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429091/
https://www.ncbi.nlm.nih.gov/pubmed/32803688
http://dx.doi.org/10.1007/s40199-020-00368-3
Descripción
Sumario:COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown to be the cellular host receptor for SARS-CoV-2. It might be the key to explain the pathogenesis of systemic complications with a focus on the direct viral cytopathic hypothesis. Different medications tend to show up in many in vitro drug screens. However, more trials are needed to translate their application into in vivo efficacy.

Ejemplares similares